PMID- 30294714
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230928
IS  - 2509-8020 (Electronic)
IS  - 2509-8020 (Linking)
VI  - 2
DP  - 2018 Dec
TI  - Psychometric evaluation of the Diabetes Injection Device Experience Questionnaire 
      (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ).
PG  - 44
LID - 10.1186/s41687-018-0064-3 [doi]
LID - 44
AB  - BACKGROUND: Previous research has examined patient perceptions of insulin 
      injection devices. However, a range of injectable medications other than insulin 
      are now used to treat type 2 diabetes. No patient-reported outcome (PRO) 
      instruments have been developed taking into account the perceptions of patients 
      using newer injection devices, which are often different from those used in the 
      past. Therefore, the primary purpose of this study was to evaluate a new PRO 
      instrument focusing on patients' experiences with injection devices, including 
      those used for newer treatments such as GLP-1 receptor agonists. METHODS: 
      Patients with T2D treated with non-insulin injectable medications were recruited 
      via advertisements and six clinical sites in the US. All participants completed 
      the draft Diabetes Injection Device - Experience Questionnaire (DID-EQ) and 
      additional measures administered for validity assessment. Participants who had 
      experience with two non-insulin injection devices also completed the draft 
      Diabetes Injection Device - Preference Questionnaire (DID-PQ). Analyses focused 
      on item reduction (item performance, exploratory factor analysis), reliability, 
      and validity. RESULTS: One hundred fourty two patients (mean age = 63.0y; 56.3% 
      female) participated. Item reduction yielded a 10-item version of the DID-EQ, 
      including a 7-item Device Characteristics subscale and three global items 
      assessing satisfaction, ease of use, and convenience of the injection device. The 
      DID-EQ demonstrated good internal consistency reliability (Cronbach's alpha of 
      Device Characteristics subscale = 0.80) and 7-day test-retest reliability (ICCs: 
      0.92 for Device Characteristics subscale; 0.65 to 0.91 for the three global 
      items). Construct validity was demonstrated via correlations with previously 
      validated instruments (e.g., correlations with the DTSQ treatment satisfaction 
      subscale ranged from 0.56 to 0.60, all p < 0.0001; correlations with the TRIM-D 
      Device ranged from 0.63 to 0.77, all p < 0.0001). Descriptive analyses of the 
      DID-PQ were conducted with a subset of 27 participants who were able to use it to 
      compare two devices. CONCLUSIONS: This psychometric evaluation supports the 
      reliability and validity of the DID-EQ, while providing initial information on 
      the performance of the DID-PQ. These brief questionnaires complement measures of 
      treatment efficacy and provide a more thorough picture of patients' experiences 
      with non-insulin injectable treatments for type 2 diabetes.
FAU - Matza, Louis S
AU  - Matza LS
AD  - 1Patient-Centered Research, Evidera, 7101 Wisconsin Avenue, Suite 1400, Bethesda, 
      MD 20814 USA. ISNI: 0000 0004 0510 2209. GRID: grid.423257.5
FAU - Stewart, Katie D
AU  - Stewart KD
AD  - 1Patient-Centered Research, Evidera, 7101 Wisconsin Avenue, Suite 1400, Bethesda, 
      MD 20814 USA. ISNI: 0000 0004 0510 2209. GRID: grid.423257.5
FAU - Paczkowski, Rosirene
AU  - Paczkowski R
AD  - 2Eli Lilly and Company, Indianapolis, IN USA. ISNI: 0000 0000 2220 2544. GRID: 
      grid.417540.3
FAU - Coyne, Karin S
AU  - Coyne KS
AD  - 1Patient-Centered Research, Evidera, 7101 Wisconsin Avenue, Suite 1400, Bethesda, 
      MD 20814 USA. ISNI: 0000 0004 0510 2209. GRID: grid.423257.5
FAU - Currie, Brooke
AU  - Currie B
AD  - 1Patient-Centered Research, Evidera, 7101 Wisconsin Avenue, Suite 1400, Bethesda, 
      MD 20814 USA. ISNI: 0000 0004 0510 2209. GRID: grid.423257.5
FAU - Boye, Kristina S
AU  - Boye KS
AD  - 2Eli Lilly and Company, Indianapolis, IN USA. ISNI: 0000 0000 2220 2544. GRID: 
      grid.417540.3
LA  - eng
PT  - Journal Article
DEP - 20180919
PL  - Germany
TA  - J Patient Rep Outcomes
JT  - Journal of patient-reported outcomes
JID - 101722688
PMC - PMC6153201
OTO - NOTNLM
OT  - GLP-1 receptor agonist
OT  - Injection device
OT  - PRO
OT  - Patient-reported outcomes measures
OT  - Psychometric validation
OT  - Type 2 diabetes
COIS- NAThis study was funded by Eli Lilly and Company (Indianapolis, IN). Kristina S. 
      Boye and Rosirene Paczkowski are employees of Eli Lilly, who provided funding for 
      this study. Louis Matza, Katie Stewart, Brooke Currie, and Karin Coyne are 
      employed by Evidera, a company that received funding from Lilly for time spent on 
      this research. All aspects of the study design, interpretation, and manuscript 
      were determined by the authors.Springer Nature remains neutral with regard to 
      jurisdictional claims in published maps and institutional affiliations.
EDAT- 2018/10/09 06:00
MHDA- 2018/10/09 06:01
PMCR- 2018/09/19
CRDT- 2018/10/09 06:00
PHST- 2018/01/12 00:00 [received]
PHST- 2018/07/09 00:00 [accepted]
PHST- 2018/10/09 06:00 [entrez]
PHST- 2018/10/09 06:00 [pubmed]
PHST- 2018/10/09 06:01 [medline]
PHST- 2018/09/19 00:00 [pmc-release]
AID - 64 [pii]
AID - 10.1186/s41687-018-0064-3 [doi]
PST - epublish
SO  - J Patient Rep Outcomes. 2018 Sep 19;2:44. doi: 10.1186/s41687-018-0064-3. 
      eCollection 2018 Dec.